Helus Pharma Presents HLP003 Analyses at Psych Congress
News related to:Helus Pharma · 2 min read
NEW YORK and TORONTO, Sept. 21, 2026 /CourierPR/ -- Helus Pharma, a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), has presented four posters at Psych Congress 2026, September 15-19, 2026, in New Orleans, Louisiana. The presentations further characterize the clinical profile of HLP003 and the Phase 3 PARADIGM program, evaluating HLP003 as a potential adjunctive treatment for Major Depressive Disorder ("MDD").
Three of the poster presentations build on findings from Helus Pharma's completed Phase 1/2a randomized, double-blind study of HLP003 as a potential adjunctive therapy in participants with MDD. Data presented includes 12-month efficacy results. A trial-in-progress overview of PARADIGM, the ongoing Phase 3 clinical program of HLP003 was also presented.
The poster number is 124.
The poster number is 123.
The poster number is 122.
The poster number is 121.
With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma™ is a trademark of Helus Pharma Corp.
Helus Pharma has presented new analyses on HLP003, a potential adjunctive treatment for Major Depressive Disorder (MDD), at the Psych Congress 2026. The presentations, which were part of a Phase 3 clinical program, characterized the clinical profile of HLP003 and included 12-month efficacy results from a completed Phase 1/2a randomized, double-blind study. The company also provided an overview of a trial-in-progress for the PARADIGM program, which aims to evaluate the efficacy and safety of HLP003 as a treatment for MDD. The company has developed proprietary serotonergic agonists (NSAs) to address mental health conditions, including depression and anxiety, and is currently developing HLP003 for the adjunctive treatment of MDD, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.